Federated Hermes
CTKB icon

Federated Hermes’s Cytek Biosciences CTKB Stock Holding History

Federated Hermes’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.9K Buy
6,078
+743
+14% +$3.17K ﹤0.01% 1760
2026
Q1 		$23.3K Buy
5,335
+756
+17% +$3.57K ﹤0.01% 1760
2025
Q4 		$23.1K Buy
4,579
+231
+5% +$1.07K ﹤0.01% 1743
2025
Q3 		$15.1K Sell
4,348
-2,873
-40% -$10.8K ﹤0.01% 1838
2025
Q2 		$24.6K Buy
7,221
+4,343
+151% +$14.5K ﹤0.01% 1693
2025
Q1 		$11.5K Sell
2,878
-4,770
-62% -$24.7K ﹤0.01% 1790
2024
Q4 		$49.6K Buy
7,648
+624
+9% +$3.72K ﹤0.01% 1666
2024
Q3 		$38.9K Buy
7,024
+2,991
+74% +$17K ﹤0.01% 1691
2024
Q2 		$22.5K Sell
4,033
-154
-4% -$925 ﹤0.01% 1707
2024
Q1 		$28.1K Buy
4,187
+191
+5% +$1.51K ﹤0.01% 1689
2023
Q4 		$36.4K Buy
+3,996
New +$25.1K ﹤0.01% 1687

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Federated Hermes's CTKB Position: Q2 2026 in Review

Federated Hermes increased its Cytek Biosciences (CTKB) stake by 14% in Q2 2026, buying an estimated $3.17K and bringing the position to 6,078 shares worth $26.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1760.

Federated Hermes first reported a position in CTKB in Q4 2023 and has held it in 11 quarters since. The position peaked at $49.6K in Q4 2024. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Federated Hermes held 6,078 shares of Cytek Biosciences worth $26.9K as of Q2 2026.
  • Federated Hermes bought 743 Cytek Biosciences shares in Q2 2026, an estimated $3.17K.
  • Cytek Biosciences made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #1760 holding.
  • Federated Hermes first reported a position in Cytek Biosciences in Q4 2023 and has held it in 11 quarters since.
  • Federated Hermes's Cytek Biosciences position peaked at $49.6K in Q4 2024.
  • 154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.